First Manhattan’s Melinta Therapeutics MLNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
– Sell
-188,985
Closed -$749K – 1488
2018
Q4
$749K Sell
188,985
-125,075
-40% -$1.6M ﹤0.01% 478
2018
Q3
$6.2M Buy
314,060
+74,060
+31% +$1.87M 0.03% 239
2018
Q2
$7.62M Buy
+240,000
New +$8.64M 0.04% 215

Other funds holding MLNT

First Manhattan's MLNT Position: Q1 2019 in Review

First Manhattan sold out of Melinta Therapeutics (MLNT) in Q1 2019, closing a stake of 188,985 shares — an estimated $749K sold.

First Manhattan first reported a position in MLNT in Q2 2018 and held it in 3 quarters. The position peaked at $7.62M in Q2 2018. 52 funds tracked by Wall St. Rank hold MLNT as of Q1 2019.

  • First Manhattan reported no remaining Melinta Therapeutics position as of Q1 2019 after selling out during the quarter.
  • First Manhattan sold 188,985 Melinta Therapeutics shares in Q1 2019, an estimated $749K.
  • First Manhattan first reported a position in Melinta Therapeutics in Q2 2018 and held it in 3 quarters.
  • First Manhattan's Melinta Therapeutics position peaked at $7.62M in Q2 2018.
  • 52 funds tracked by Wall St. Rank held Melinta Therapeutics as of Q1 2019.

Based on First Manhattan's 13F filing for Q1 2019, filed 12 Apr 2019.